Status:
COMPLETED
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Europe B.V.
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
Eligibility Criteria
Inclusion
- Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months
Exclusion
- Pregnant and breastfeeding women
- Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
1108 Patients enrolled
Trial Details
Trial ID
NCT00337090
End Date
March 1 2007
Last Update
July 2 2013
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
3 Sites
Antwerp, Belgium
2
2 Sites
Brussels, Belgium
3
Ghent, Belgium
4
Leuven, Belgium